KLARIA PHARMA Aktie

 

Klaria Pharma Holding AB Annual Report 2024 The year in brief - Net sales amounted to 2.2 MSEK (8.5 MSEK) - Other operating income amounted to 0.1 MSEK (0.5 MSEK) - R&D costs amounted to 22.1 MSEK (25.0 MSEK) - Profit/loss after tax amounted to -47.8 MSEK (-35.8 MSEK) - Earnings per share amounted to -0.38 SEK (-0.36 SEK) - Cash flow from operations amounted to -11.9 MSEK (-9.1 MSEK) - Shareholder's equity as of December 31, 2024 amounted to 3.3 MSEK (41.1 MSEK) - Cash and cash equivalents as of December 31, 2024 amounted to 0.6 MSEK (1.2 MSEK)...

Klaria Pharma Holding AB (publ) ("Klaria" or the "Company") announces that the Company has signed a license agreement for Sumatriptan Alginate Film (the "Product"), a pharmaceutical product based on Klaria's patented alginate films for fast and reliable administration via the oral mucosa, which is approved in Germany, Spain and Italy for the treatment of migraine with or without aura, with CNX Therapeutics Limited (“CNX Therapeutics”). The agreement gives CNX Therapeutics the right to market and sell the Product in Europe and the UK under its own brand and product name, and the parties plan...